8-K: Marker Therapeutics Secures Key Manufacturing Partnership for Lead Lymphoma Therapy MT-601

Marker Therapeutics, Inc. announced a strategic collaboration with Cellipont Bioservices for the cGMP manufacturing of its lead Multi-Antigen Recognizing (MAR)-T cell therapy, MT-601, to support its APOLLO study and future commercial readiness.

Summary

• Marker Therapeutics, Inc. (Nasdaq: MRKR) entered into a Statement of Work (SOW) with Cellipont Bioservices on June 16, 2025, for the manufacturing of MT-601.
• MT-601 is Marker's lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently being investigated in the Phase 1 APOLLO study (clinicaltrials.gov identifier: NCT05798897) for patients with lymphoma who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapy.
• Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), will provide technology transfer and current good manufacturing practice (cGMP) manufacturing services.
• The SOW outlines the terms for the technology transfer of Marker's MT-601 manufacturing and testing processes and procedures over the following nine months.
• Previous clinical data for MT-601, reported on December 19, 2024, indicated a favorable safety profile and objective responses in 7 out of 9 study participants (78%), with 4 participants achieving complete response (44.4%) as early as 4 weeks after infusion.
• This collaboration is designed to accelerate clinical supply and establish the foundation for a potential pivotal trial and commercial readiness for MT-601, particularly for diffuse large B-cell lymphoma (DLBCL) patients.

Sentiment

Score: 8

Explanation: The announcement of a strategic manufacturing partnership for a lead clinical asset is a significant positive development, indicating progress towards pivotal trials and potential commercialization. This de-risks the manufacturing pathway for MT-601, which has already shown promising early clinical data.

Positives

• The agreement with Cellipont Bioservices secures a critical cGMP manufacturing partner, which is essential for scaling up production of MT-601.
• This partnership is a significant step towards advancing MT-601 into potential pivotal trials and eventual commercialization.
• Cellipont's expertise and state-of-the-art 76,000-square-foot facility are expected to support high-quality and scalable cell therapy production.
• The collaboration aims to accelerate the clinical supply of MT-601 for the ongoing APOLLO study.
• The promising clinical data previously observed in the APOLLO study (78% objective response, 44.4% complete response) reinforces the potential of MT-601 to address an unmet medical need.

Risks

• Risks associated with the Company's research, development, and regulatory activities concerning its non-engineered multi-antigen recognizing T cell therapies.
• Uncertainties regarding the manufacturing capabilities of the Company's CDMO partners.
• Risks related to the effectiveness of these programs or the possible range of application, potential curative effects, and safety in the treatment of diseases.
• Uncertainties regarding the timing, conduct, interim results announcements, and outcomes of clinical trials for product candidates, including MT-601 for lymphoma.

Future Outlook

Marker Therapeutics aims to accelerate the clinical supply of MT-601 and establish the foundation for a potential pivotal trial and commercial readiness. The company is preparing for a potential pivotal trial of MT-601 in patients with diffuse large B-cell lymphoma (DLBCL) who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapy. Marker's overarching goal is to introduce novel T cell therapies to the market and improve patient outcomes, while prioritizing the preservation of financial resources and operational excellence.

Management Comments

• "This exciting collaboration with Cellipont is a critical step forward as we prepare for a potential pivotal trial of MT-601 in patients with diffuse large B-cell lymphoma (DLBCL) who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapy." Dr. Juan Vera, President and CEO of Marker Therapeutics.
• "The promising clinical data we have observed in the ongoing APOLLO study reinforce our commitment to advancing MT-601 to address an important area of unmet need." Dr. Juan Vera, President and CEO of Marker Therapeutics.
• "We sought a manufacturing partner with the capabilities to support not only mid-to-late-stage clinical development but also future commercial production, and we believe Cellipont is well positioned to support us as we advance our program through the next stages." Dr. Juan Vera, President and CEO of Marker Therapeutics.
• "We are proud to support Marker Therapeutics in advancing MT-601, a compelling MAR-T cell therapy that is anticipated to address a major need in the cell therapy space." Darren Head, CEO of Cellipont Bioservices.
• "Our team is dedicated to enabling the success of next-generation immunotherapies, and Markers platform exemplifies the innovation and translational potential that defines the future of cancer treatment." Darren Head, CEO of Cellipont Bioservices.

Industry Context

This collaboration reflects a broader industry trend in the biopharmaceutical sector, particularly within advanced therapies like cell and gene therapies, where companies increasingly partner with specialized Contract Development and Manufacturing Organizations (CDMOs). This strategy allows clinical-stage companies like Marker Therapeutics to leverage external expertise and infrastructure for complex cGMP manufacturing, accelerating development timelines and preparing for commercial scale. The focus on lymphoma patients who have failed or are ineligible for existing CAR-T therapies highlights a critical unmet need within the oncology landscape, positioning MT-601 in a high-demand therapeutic area.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark against industry standards for manufacturing partnerships or clinical outcomes.
• Cellipont Bioservices' facility is described as 76,000-square-foot with modular cleanrooms, integrated QC labs, and advanced closed processing systems, which are standard features for a modern cell therapy CDMO.
• The reported clinical data for MT-601 (78% objective response rate, 44.4% complete response rate in 9 patients) are promising for a Phase 1 study in a challenging patient population, but a detailed comparison to other therapies would require more comprehensive clinical trial data and context not provided in this announcement.

Stakeholder Impact

• **Shareholders:** Likely positive impact due to the advancement of the lead clinical program, which could enhance the company's valuation and future prospects.
• **Patients:** Potential positive impact as the collaboration aims to accelerate the development and eventual availability of MT-601, offering a new therapeutic option for lymphoma patients with unmet needs.
• **Employees:** May experience increased job security and potential growth opportunities as the company progresses its lead asset towards commercialization.
• **Suppliers:** Cellipont Bioservices benefits directly from this new contract, and other suppliers to both Marker and Cellipont may see increased demand for their products and services.

Next Steps

• Cellipont Bioservices will provide technology transfer and cGMP manufacturing services for MT-601 over the following nine months.
• Accelerate clinical supply of MT-601 for the APOLLO study.
• Lay the foundation for a potential pivotal trial of MT-601.
• Prepare for future commercial production of MT-601.

Key Dates

Recommendation

Keywords

Marker Therapeutics, Cellipont Bioservices, MT-601, MAR-T cell therapy, cGMP manufacturing, immuno-oncology, lymphoma, APOLLO study, clinical-stage, cell therapy, CDMO, hematological malignancies, solid tumors, CAR-T cell therapy, diffuse large B-cell lymphoma, DLBCL